Eckel Invited Lecture: Evaluating And Treating Residual Risk In Ascvd | Michael J. Blaha, Md, Mph

Eckel Invited Lecture: Evaluating and Treating "Residual Risk" in ASCVD | Michael J. Blaha, MD, MPH

University of Colorado | Department of Medicine

Beyond LDL: Assessing and Treating Residual ASCVD Risk | Marc-Andre Cornier, MD

University of Colorado | Department of Medicine

Optimizing Lipid Risk Factors: Focus on Residual Risk, Dr. David Vorchheimer

MonteHeart Lectures

New evidence in heart disease - Reducing residual risk

ESC Guidelines: Risk Factors of ASCVD (English Version)

CardioMinds, Dr. Sherif Altoukhy

Cardiovascular Testing, A Functional Medicine Approach

DrPatrickKrupka

Interview with Prof Fanelli: Latest evidence on the safety of paclitaxel Part 1

iVascular - Dispositivos Cardiovasculares

Mohamad Alkhouli on Clinical Impact of Residual Leaks Following LAAO | ACC.22 SimPub

American College of Cardiology

A Patient's Guide to Understanding Risk

Vasculearn Network

How important is residual inflammatory risk to residual vascular risk?

ISEV23 Education Day: EV release and uptake - Alissa Weaver

EVClub: Extracellular Vesicle Club

ESC Guidelines: Risk Stratification in Established ASCVD (English Version)

CardioMinds, Dr. Sherif Altoukhy

Ahmed Ibrahim and Alessandra Ciullo: Single-RNA tracking for cardiosphere EV biodistribution studies

EVClub: Extracellular Vesicle Club

Dr. Eric Okum – Intraoperative Testing of the Posterior Left Atrium During Surgical Ablation

Symposium On: Residual CV Risk: IS LDL-C Target Enough?

What does the SPPARMα concept offer for management of residual vascular risk?

ICER's Use of the QALY and the evLYG

Institute for Clinical and Economic Review (ICER)

ESC Guidelines: Risk Stratification in Apparently Healthy (English Version)

CardioMinds, Dr. Sherif Altoukhy